Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect strong interest and recognition of the study's importance, with phrases like 'hot off the press' and notes that RBX2660 is 'safe & effective' indicating positive reception. The tone varies from eager curiosity to serious analysis, especially when mentioning the regulatory context and methodological details, which show engagement and recognition of the potential impact on treatment and policy.
Most discussions support the positive findings of the publication, emphasizing its clinical success and safety, as seen in expressions like 'RBX2660 is safe & effective' and references to the trial's favorable outcomes.
The overall tone indicates high curiosity and relevance; many posts highlight the significance of the trial results by calling it 'hot off the press' and emphasizing the potential of RBX2660 for preventing recurrent infections.
Several discussions delve into method details, such as mentioning the Bayesian analysis, and compare the new treatment to existing options, demonstrating deeper engagement with the research and its implications.
The posts suggest a perception that this publication could influence clinical practices and regulatory decisions, especially considering mentions of FDA panel meetings and the potential of the medication to revolutionize treatment for recurrent C. diffici
Such a trial might have given rise to a very different regulatory outcome, because the cure rate reported by Rebyota is much lower than the cure rate from Openbiome's own interventions: https://t.co/EAuDhVaU7O 27/
1/8 #EBGI
Hot off the press ➡️Phase III data: #RBX2660 is safe & effective for recurrent #Cdifficile infection ➡️Standardized non-invasive single-dose enema-based Rx after standard of care antibiotics @Rebiotix @FerringMBiome @ferring @FerringUSA @DrugsJournal https://t.co/jTwAXZ9ide
FDA Approves First Fecal Microbiota Product: Rebyota Approved for the Prevention of Recurrence of CDI in Adults https://t.co/UgLxMMv6A8 RBX2660 is safe? https://t.co/icEh1AFvTq Darmflora: Erstes Medikament aus menschlichen Stuhlproben zugelassen https://t.co/TCSUCXg3zK @_atanas_
@LaughingTroll1 @f2harrell See https://t.co/TJ7BzbIlKd for an FDA panel meeting preceding an approval of RBX2660. Statistical discussion starting at 3:28:00 and includes an informative prior based on historical data. Paper available at https://t.co/qVDMXLHCUr One example among many
Khanna et al analyze the efficacy and safety of RBX2660 in preventing recurrent Clostridioides difficile infections in a Phase III trial using Bayesian analysis. Results show a 70.6% success rate with RBX2660…
●CD感染再発防止のための糞便移植(FMT)の有効性と安全性のRCT CID PMID: 36287379 →FMTはプラセボと比較し、56 日時点での CD再発または死亡率を低下させなかった。治療グループ間で有害事象に有意差はなし https://t.co/RvY4AUqryL
@LaughingTroll1 @f2harrell See https://t.co/TJ7BzbIlKd for an FDA panel meeting preceding an approval of RBX2660. Statistical discussion starting at 3:28:00 and includes an informative prior based on historical data. Paper available at https://t.co/qVDMXLHCUr One example among many
RT @doctorow: Such a trial might have given rise to a very different regulatory outcome, because the cure rate reported by Rebyota is much…
RT @doctorow: Such a trial might have given rise to a very different regulatory outcome, because the cure rate reported by Rebyota is much…
RT @doctorow: Such a trial might have given rise to a very different regulatory outcome, because the cure rate reported by Rebyota is much…
Such a trial might have given rise to a very different regulatory outcome, because the cure rate reported by Rebyota is much lower than the cure rate from Openbiome's own interventions: https://t.co/EAuDhVaU7O 27/
RT @AmCollegeGastro: 1/8 #EBGI
RT @AmCollegeGastro: 1/8 #EBGI
RT @AmCollegeGastro: 1/8 #EBGI
1/8 #EBGI
RT @erlesen: FDA Approves First Fecal Microbiota Product: Rebyota Approved for the Prevention of Recurrence of CDI in Adults https://t.co/U…
RT @erlesen: FDA Approves First Fecal Microbiota Product: Rebyota Approved for the Prevention of Recurrence of CDI in Adults https://t.co/U…
RT @erlesen: FDA Approves First Fecal Microbiota Product: Rebyota Approved for the Prevention of Recurrence of CDI in Adults https://t.co/U…
RT @erlesen: FDA Approves First Fecal Microbiota Product: Rebyota Approved for the Prevention of Recurrence of CDI in Adults https://t.co/U…
FDA Approves First Fecal Microbiota Product: Rebyota Approved for the Prevention of Recurrence of CDI in Adults https://t.co/UgLxMMv6A8 RBX2660 is safe? https://t.co/icEh1AFvTq Darmflora: Erstes Medikament aus menschlichen Stuhlproben zugelassen https://t.co/TCSUCXg3zK @_atanas_
RT @ABsteward:
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection - PubMed:… https://t.co/LIphisYxfF #cdiff #cdi #fmt
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection https://t.co/J3gWzahIjb
RT @ABsteward:
RT @Khanna_S: Hot off the press ➡️Phase III data: #RBX2660 is safe & effective for recurrent #Cdifficile infection ➡️Standardized non-inva…
RT @ABsteward:
RT @ABsteward:
RT @Khanna_S: Hot off the press ➡️Phase III data: #RBX2660 is safe & effective for recurrent #Cdifficile infection ➡️Standardized non-inva…
Hot off the press ➡️Phase III data: #RBX2660 is safe & effective for recurrent #Cdifficile infection ➡️Standardized non-invasive single-dose enema-based Rx after standard of care antibiotics @Rebiotix @FerringMBiome @ferring @FerringUSA @DrugsJournal https://t.co/jTwAXZ9ide
RT @ABsteward:
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection https://t.co/xTzyGPpRI8 #cdiff #cdi
Just published in @DrugsJournal phase 3 PUNCH-CD3 trial results showing RBX2660 is superior to placebo in preventing recurrence of C. difficile infection https://t.co/lsS5S2Igka
Khanna, S., et al. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs (2022). https://t.co/yofI93llQj